• Mind Medicine (MindMed) Inc MNMD.OQ reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of nine analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -40 cents to -29 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Mind Medicine (MindMed) Inc's reported EPS for the quarter was a loss of 50 cents​.

• The company reported a quarterly loss of $42.74 million.

• Mind Medicine (MindMed) Inc shares had risen by 39.1% this quarter and gained 29.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Mind Medicine (MindMed) Inc is $20.00, about 54.9% above its last closing price of $9.03

This summary was machine generated from LSEG data July 31 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)